Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/-p53-/- mice

Cancer Cell

Volumn 6, Issue 3, 2004, Pages 229-240

  Romer, Justyna T ^a   Kimura, Hiromichi ^a   Magdaleno, Susan ^a   Sasai, Ken ^a   Fuller, Christine ^a   Baines, Helen ^a   Connelly, Michele ^a   Stewart, Clinton F ^a   Gould, Stephen ^b   Rubin, Lee L ^b   Curran, Tom ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CURIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN;

ARTICLE; BRAIN TUMOR; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; DRUG MEGADOSE; GENE EXPRESSION; GENE REPRESSION; MEDULLOBLASTOMA; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SURVIVAL; TUMOR GROWTH;

ERINACEIDAE;

EID: 4544285754     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.08.019     Document Type: Article

References (46)

1. Akagi T., Sasai K., Hanafusa H. Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc. Natl. Acad. Sci. USA. 100:2003;13567-13572
2. Aszterbaum M., Rothman A., Johnson R.L., Fisher M., Xie J., Bonifas J.M., Zhang X., Scott M.P., Epstein E.H. Jr. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol. 110:1998;885-888
3. Bai C.B., Auerbach W., Lee J.S., Stephen D., Joyner A.L. Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development. 129:2002;4753-4761
4. Berman D.M., Karhadkar S.S., Hallahan A.R., Pritchard J.I., Eberhart C.G., Watkins D.N., Chen J.K., Cooper M.K., Taipale J., Olson J.M., Beachy P.A. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science. 297:2002;1559-1561
5. Berman D.M., Karhadkar S.S., Maitra A., Montes De Oca R., Gerstenblith M.R., Briggs K., Parker A.R., Shimada Y., Eshleman J.R., Watkins D.N., Beachy P.A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 425:2003;846-851
6. Binns W., James L.F., Shupe J.L., Everett G. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, Veratrum californicum. Am. J. Vet. Res. 24:1963;1164-1175
7. Chen J.K., Taipale J., Cooper M.K., Beachy P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16:2002;2743-2748
8. Chintagumpala M., Berg S., Blaney S.M. Treatment controversies in medulloblastoma. Curr. Opin. Oncol. 13:2001;154-159
9. Cooper M.K., Porter J.A., Young K.E., Beachy P.A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 280:1998;1603-1607
10. Corcoran R.B., Scott M.P. A mouse model for medulloblastoma and basal cell nevus syndrome. J. Neurooncol. 53:2001;307-318
11. Ellison D. Classifying the medulloblastoma. insights from morphology and molecular genetics Neuropathol. Appl. Neurobiol. 28:2002;257-282
12. Ellison D.W., Clifford S.C., Gajjar A., Gilbertson R.J. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur. J. Paediatr. Neurol. 7:2003;53-66
13. Frank A.J., Hernan R., Hollander A., Lindsey J.C., Lusher M.E., Fuller C.E., Clifford S.C., Gilbertson R.J. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res. Mol. Brain Res. 121:2004;137-140
14. Furuya S., Makino A., Hirabayashi Y. An improved method for culturing cerebellar Purkinje cells with differentiated dendrites under a mixed monolayer setting. Brain Res. Brain Res. Protoc. 3:1998;192-198
15. Gabay L., Lowell S., Rubin L.L., Anderson D.J. Deregulation of dorsoventral patterning by FGF confers trilineage differentiation capacity on CNS stem cells in vitro. Neuron. 40:2003;485-499
16. Goodrich L.V., Scott M.P. Hedgehog and patched in neural development and disease. Neuron. 21:1998;1243-1257
17. Goodrich L.V., Milenkovic L., Higgins K.M., Scott M.P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 277:1997;1109-1113
18. Gorlin R.J. Nevoid basal cell carcinoma syndrome. Dermatol. Clin. 13:1995;113-125
19. Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A., Vorechovsky I., Holmberg E., Unden A.B., Gillies S., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 85:1996;841-851
20. Hesselager G., Holland E.C. Using mice to decipher the molecular genetics of brain tumors. Neurosurgery. 53:2003;685-695
21. Johnson R.L., Rothman A.L., Xie J., Goodrich L.V., Bare J.W., Bonifas J.M., Quinn A.G., Myers R.M., Cox D.R., Epstein E.H. Jr., Scott M.P. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 272:1996;1668-1671
22. Kalbfleisch J.D., Prentice R.L. Statistical Analysis of Failure Time Data. 1980;Wiley, New York
23. Keeler R.F., Binns W. Teratogenic compounds of Veratrum californicum (Durand). V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources. Teratology. 1:1968;5-10
24. Kimonis V.E., Goldstein A.M., Pastakia B., Yang M.L., Kase R., DiGiovanna J.J., Bale A.E., Bale S.J. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am. J. Med. Genet. 69:1997;299-308
25. Kleihues P., Schauble B., zur Hausen A., Esteve J., Ohgaki H. Tumors associated with p53 germline mutations. a synopsis of 91 families Am. J. Pathol. 150:1997;1-13
26. Kruskal W.H., Wallis W.A. Use of ranks in one-criterion variance analysis. J. Am. Stat. Assoc. 47:1952;583-621
27. Lee Y., Miller H.L., Jensen P., Hernan R., Connelly M., Wetmore C., Zindy F., Roussel M.F., Curran T., Gilbertson R.J., McKinnon P.J. A molecular fingerprint for medulloblastoma. Cancer Res. 63:2003;5428-5437
28. Li L., Connelly M.C., Wetmore C., Curran T., Morgan J.I. Mouse embryos cloned from brain tumors. Cancer Res. 63:2003;2733-2736
29. Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238
30. Park H.L., Bai C., Platt K.A., Matise M.P., Beeghly A., Hui C.C., Nakashima M., Joyner A.L. Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development. 127:2000;1593-1605
31. Reifenberger J., Wolter M., Weber R.G., Megahed M., Ruzicka T., Lichter P., Reifenberger G. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 58:1998;1798-1803
32. Rice D.S., Sheldon M., D'Arcangelo G., Nakajima K., Goldowitz D., Curran T. Disabled-1 acts downstream of Reelin in a signaling pathway that controls laminar organization in the mammalian brain. Development. 125:1998;3719-3729
33. Sasaki H., Hui C., Nakafuku M., Kondoh H. A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro. Development. 124:1997;1313-1322
34. Shapiro S.S., Wilk M.B. An analysis of variance test for normality (complete samples). Biometrika. 52:1965;591-611
35. Taipale J., Chen J.K., Cooper M.K., Wang B., Mann R.K., Milenkovic L., Scott M.P., Beachy P.A. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 406:2000;1005-1009
36. Taipale J., Cooper M.K., Maiti T., Beachy P.A. Patched acts catalytically to suppress the activity of Smoothened. Nature. 418:2002;892-897
37. Taylor M.D., Liu L., Raffel C., Hui C.C., Mainprize T.G., Zhang X., Agatep R., Chiappa S., Gao L., Lowrance A., et al. Mutations in SUFU predispose to medulloblastoma. Nat. Genet. 31:2002;306-310
38. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernandez-del Castillo C., Yajnik V., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 425:2003;851-856
39. Van Dyke T., Jacks T. Cancer modeling in the modern era. progress and challenges Cell. 108:2002;135-144
40. Wechsler-Reya R., Scott M.P. The developmental biology of brain tumors. Annu. Rev. Neurosci. 24:2001;385-428
41. Weiner H.L., Bakst R., Hurlbert M.S., Ruggiero J., Ahn E., Lee W.S., Stephen D., Zagzag D., Joyner A.L., Turnbull D.H. Induction of medulloblastomas in mice by sonic hedgehog, independent of Gli1. Cancer Res. 62:2002;6385-6389
42. Wetmore C., Eberhart D.E., Curran T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res. 60:2000;2239-2246
43. Wetmore C., Eberhart D.E., Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 61:2001;513-516
44. Williams J.A., Guicherit O.M., Zaharian B.I., Xu Y., Chai L., Wichterle H., Kon C., Gatchalian C., Porter J.A., Rubin L.L., Wang F.Y. Identification of a small molecule inhibitor of the hedgehog signaling pathway. effects on basal cell carcinoma-like lesions Proc. Natl. Acad. Sci. USA. 100:2003;4616-4621
45. Xie J., Johnson R.L., Zhang X., Bare J.W., Waldman F.M., Cogen P.H., Menon A.G., Warren R.S., Chen L.C., Scott M.P., Epstein E.H. Jr. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res. 57:1997;2369-2372
46. Zurawel R.H., Allen C., Wechsler-Reya R., Scott M.P., Raffel C. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer. 28:2000;77-81